Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Small cell lung cancer (SCLC) is a highly aggressive cancer with a dismal 5‐year survival of < 7%, despite the addition of immunotherapy to first‐line chemotherapy. Specific tumor biomarkers, such as delta‐like ligand 3 (DLL3) and schlafen11 (SLFN11), may enable the selection of more efficacious,...

Full description

Saved in:
Bibliographic Details
Main Authors: Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico vanZandwijk, John E. J. Rasko, Dannel Yeo
Format: Article
Language:English
Published: Wiley 2025-07-01
Series:Molecular Oncology
Subjects:
DLL3
liquid biopsy
schlafen11
targeted therapies
tarlatamab
thoracic oncology
Online Access:https://doi.org/10.1002/1878-0261.13696
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items